1.00

7.41% -0.08

VolitionRX Ltd (VNRX)

Overview News Price History Option Chain Discussions Forecast

VolitionRX Ltd stock is traded at $1.00, with a volume of 171.12K. It is down -7.41% in the last 24 hours and down -18.70% over the past month. VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Previous Close:

$1.08

Open:

$1.1

24h Volume:

171.12K

Relative Volume:

0.60

Market Cap:

$12.04M

Revenue:

$2.47M

Net Income/Loss:

$-24.73M

P/E Ratio:

-0.2374

EPS:

-4.213

Net Cash Flow:

$-20.36M

1W Performance:

-9.09%

1M Performance:

-18.70%

6M Performance:

-82.27%

1Y Performance:

-93.15%

1-Day Range:

$0.99

$1.10

1-Week Range:

$0.99

$1.1892

52-Week Range:

$0.99

$16.00

VolitionRX Ltd Stock (VNRX) Company Profile

Name

VolitionRX Ltd

Sector

Healthcare (1071)

Industry

Diagnostics & Research (48)

Phone

646 650 1351

Address

No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX

Employee

Twitter

@VolitionRx

Next Earnings Date

2026-08-13

Latest SEC Filings

VNRX's Discussions on Twitter

Compare VNRX vs TMO, DHR, IDXX, A, NTRA

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNRX VolitionRX Ltd	1.00	12.04M	2.47M	-24.73M	-20.36M	-4.213
TMO Thermo Fisher Scientific Inc	568.26	211.18B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	191.50	134.62B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	544.32	42.94B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	138.57	39.14B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.99	37.52B	2.50B	-226.32M	71.51M	-1.6412

VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-25	Initiated	H.C. Wainwright	Buy
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight
May-16-18	Initiated	Maxim Group	Buy
May-14-18	Reiterated	The Benchmark Company	Buy
Sep-07-16	Reiterated	Rodman & Renshaw	Buy
Feb-01-16	Initiated	Rodman & Renshaw	Buy

View All

VolitionRX Ltd Stock (VNRX) Latest News

Jul 21, 2026

VolitionRx Limited Amends Certificate of Incorporation: SEC Filing Details and XBRL Data 10 - Minichart

Jul 21, 2026

Jul 20, 2026

VOLITIONRX LTD SEC Filing (Jul 20, 2026) - Stock Titan

Jul 20, 2026

Jul 11, 2026

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution - Yahoo Finance

Jul 11, 2026

Jul 10, 2026

VolitionRX (VNRX) Registration filing Summary - Quartr

Jul 10, 2026

VNRX Announces Sale of 3.31 Million Shares by Selling Stockholders - GuruFocus

Jul 10, 2026

VolitionRx (NYSE: VNRX) files to register 3.3M Lind-linked shares for resale - Stock Titan

Jul 10, 2026

Jul 08, 2026

Maxim Group Maintains VolitionRX(VNRX.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Jul 08, 2026

Jul 07, 2026

VolitionRx Ltd explores blood-based cancer diagnostics as investors watch VNRX - ad-hoc-news.de

Jul 07, 2026

VolitionRx releases lung cancer prognostic study data - Investing.com

Jul 07, 2026

VolitionRx releases lung cancer prognostic study data By Investing.com - Investing.com Australia

Jul 07, 2026

VolitionRx’s lung cancer test could help doctors predict outcomes - Stock Titan

Jul 07, 2026

VolitionRX Announces Data Showing the Prognos - Moomoo

Jul 07, 2026

Jul 06, 2026

VolitionRx prices $4.6 million public offering at $1.55 per share By Investing.com - Investing.com UK

Jul 06, 2026

Jun 27, 2026